引用次数
引用: 45,695
H-指数: 96
I10-指数 : 340
出版物: 1,218
The EORTC Gastrointestinal Tract Cancer Group: 50 years of research contributing to improved gastrointestinal cancer management
Gustavo Werutsky , Michel Ducreux , Manfred Lutz , Murielle Mauer
Ejc Supplements 10 ( 1) 51 -57
4
2012
Outcomes of patients with squamous cell carcinoma of esophagus who did not receive surgical resection after neoadjuvant radiochemotherapy.
Khashayar Fakhrian , Arif Deniz Ordu , Carsten Nieder , Florian Lordick
Tumori 101 ( 3) 263 -267
1
2015
Quality of life in survivors of hematological malignancies stratified by cancer type, time since diagnosis and stem cell transplantation.
Peter Esser , Katharina Kuba , Anja Mehnert , Christoffer Johansen
European Journal of Haematology 101 ( 3) 340 -348
8
2018
Prognostic factors for the efficacy of catumaxomab in patients (pts) with malignant ascites (MA): Meta-analysis from two phase III studies.
Hilke Friccius-Quecke , Markus M. Heiss , Florian Lordick , Simon L. Parsons
Journal of Clinical Oncology 31 3078 -3078
2013
Cetuximab and chemotherapy in the treatment of patients with initially “nonresectable” colorectal (CRC) liver metastases: Long-term follow-up of the CELIM trial.
Gunnar Folprecht , Thomas Gruenberger , Wolf Bechstein , Hans-Rudolf Raab
Journal of Clinical Oncology 31 3538 -3538
5
2013
Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study.
Florian Lordick , Yoon-Koo Kang , Pamela Salman , Sang Cheul Oh
Journal of Clinical Oncology 31 4021 -4021
20
2013
Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas.
Martin H. Schuler , Zanete Zvirbule , Florian Lordick , Anna Krilova
Journal of Clinical Oncology 31 4080 -4080
19
2013
EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): An open-label randomized controlled phase II study.
Elizabeth Catherine Smyth , Maren Kristina Knoedler , Magnus Nilsson , Anna Dorothea Wagner
Journal of Clinical Oncology 38
2
2020
Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2+/HER2−advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW.
Manish A. Shah , Jaffer A. Ajani , Salah-Eddin Al-Batran , Yung-Jue Bang
Journal of Clinical Oncology 38
1
2020
Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.
Joseph Chao , Elvira Buxó , Andrés Cervantes , Farshid Dayyani
Journal of Clinical Oncology 38
1
2020
Comparison of pretherapeutic and posttherapeutic expression levels of chemotherapy-associated genes in adenocarcinomas of the esophagus treated by 5-fluorouracil- and cisplatin-based neoadjuvant chemotherapy.
Jörg-Rüdiger Siewert , Heinz Höfler , Rupert Langer , Katja Specht
American Journal of Clinical Pathology 128 ( 2) 191 -197
24
2007
Welche Tumorpatienten profitieren von einer interdisziplinären Psychoedukation im Rahmen der Tumortherapie
Harald Gündel , Verena Hümmeler , Florian Lordick
Zeitschrift Fur Psychosomatische Medizin Und Psychotherapie 53 ( 4) 324 -338
12
2007
Two steps forward and one step back.
Florian Lordick , Elizabeth C. Smyth
Nature Reviews Clinical Oncology 16 ( 2) 69 -70
4
2019
Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study
Chiara Alessandra Cella , Giovanni Di Minno , Chiara Carlomagno , Michele Arcopinto
Oncologist 22 ( 5) 601 -608
102
2017
Anti-angiogenesis: disappointment in localised oesophagogastric cancer
Florian Lordick
The Lancet Oncology 18 ( 3) 278 -279
1
2017
Definitive or neoadjuvant chemoradiotherapy for squamous cell oesophageal cancer?
David Ilson , Florian Lordick
The Lancet Oncology 19 ( 10) 1285 -1286
6
2018
Social networks for young patients with cancer: the time for system agility.
Irit Ben-Aharon , Tal Goshen-Lago , Elisa Fontana , Elizabeth Smyth
Lancet Oncology 20 ( 6) 765
3
2019
Nivolumab for previously treated squamous oesophageal carcinoma.
Elizabeth C Smyth , Florian Lordick
Lancet Oncology 20 ( 11) 1468 -1469
4
2019
Chemotherapy for resectable microsatellite instability-high gastric cancer?
Florian Lordick
The Lancet Oncology 21 ( 2) 203
8
2020
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
Ignace Vergote , Giovanni Scambia , David M O'Malley , Ben Van Calster
Lancet Oncology 20 ( 6) 862 -876
24
2019